メタゲノムシーケンスの世界市場-2022-2029

市場力学

メタゲノムシーケンスの世界市場の成長は、先進的な技術プラットフォームや改良されたゲノムツール、政府および民間組織による大規模なシーケンスプロジェクトに対する取り組みや資金の増加といった特定の要因によって牽引されており、市場成長の主要な要因の一つとなっています。

先進的な技術プラットフォームと改良されたゲノムツールは、予測期間中に世界のメタゲノムシーケンス市場を牽引することが期待されます。

メタゲノムシーケンス市場の成長を促進する主な要因の1つは、より高速なシーケンス技術の継続的な開発と、生成された膨大なデータに対処するためのさまざまな方法の進歩で、無限のさまざまな環境から微生物コミュニティを分析する研究者の能力が拡大しています。

高度なバイオインフォマティクスツール、ハイスループットスクリーニング（HTS）手法、新薬の回収、次世代シーケンサー（NGS）などの費用対効果の高い技術の開発の採用が進んでいることが、市場成長の原動力となっています。次世代DNAシーケンス（NGS）技術の開発は、分子生物学研究を推進し、いくつかの発見と新しい洞察につながりました。次世代DNAシーケンシング技術は、分子生物学の原理を越えて到達するその応用により、長く確立されたDNAシーケンシングを超えるものです。

2019年5月28日、精密医療バイオテクノロジー企業であるマクロジェン社は、韓国の食品医薬品安全部（MFDS）から臨床試験実施優良施設の認定を受け、臨床試験検体分析機関として指定されました。この認定は、臨床診断用メタゲノミクスを向上させ、Macrogen社に利益をもたらすでしょう。

したがって、DNAシーケンシングに関する技術的進歩の増加は、予測期間中の市場成長を促進することが期待されます。

政府および民間組織によるシーケンシングの大規模プロジェクトに対する取り組みや資金の増加

遺伝性疾患に対する意識の高まりや、シーケンシングの大規模プロジェクトに対する政府の取り組みや資金の増加は、世界のメタゲノムシーケンス市場の成長を促進する主な要因の一つです。例えば、2019年にQIAGENは、マンチェスター（英国）の世界ゲノミクスキャンパスを支援・設立するために、英国の複数の組織とパートナーシップを締結しました。新しいGenomic Health Innovation Campusは、生命科学、トランスレーショナルサイエンス、分子診断分野でのイノベーションを目指します。

また、2019年11月、第14回国際ゲノミクス会議（ICG-14）において、The"Million Microbiome of Humans Project"（MMHP）が正式に開始されました。中国、フランス、スウェーデン、デンマーク、ラトビアなどの科学者が協力して微生物のメタゲノム研究を行い、今後3～5年で腸、皮膚、口腔、生殖管などから100万個の微生物サンプルの配列と解析を行って人体のマイクロバイオームマップを描き、世界最大のヒトマイクロバイオームデータベースを構築することを目指しています。

メタゲノムシーケンス市場の成長を阻害する要因

しかし、診断テストの標準化と精度に対する懸念の高まり、さまざまな分離・同定技術の並行的な進歩に対する要求、より効率的で堅牢なバイオインフォマティクスツール、熟練した専門家の不足など、いくつかの要因が市場の成長を妨げています。

セグメンテーション分析

ショットガンメタゲノムシーケンス技術セグメントは、予測期間中（2022-2029）に最も速いCAGRで成長すると予想されます。

メタゲノムシーケンス市場は、技術別に、16S rRNAシーケンス、ショットガンメタゲノムシーケンス、ホールゲノムシーケンス＆デノボアセンブリ、メタトランススクリプトミクスに区分されます。これらのセグメントのうち、研究者やヘルスケア専門家の間でショットガンメタゲノムシーケンスの採用が進んでいること、その他の技術と比較してショットガンシーケンスが提供するいくつかの利点、メタゲノムシーケンスに基づく研究活動の増加などにより、予測期間中にショットガンメタゲノムシーケンス技術が最も速い成長率で伸びています。ショットガンシーケンスでは、微生物コミュニティの低存在量のメンバーを検出することができます。ショットガンメタゲノムシーケンスは、ホールシーケンスと対照的に、環境サンプルで見つかったすべての生物からすべての遺伝子をターゲットにすることができ、1つの生物のみからすべての遺伝子をターゲットにすることができます。

世界のメタゲノムシーケンス市場レポートでは、約40以上の市場データ表、45以上の図、180ページへのアクセスを提供します。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

• 製品・サービス別市場内訳
• 技術別市場内訳
• ワークフロー別市場内訳
• アプリケーション別市場内訳
• 地域別市場内訳

第4章 市場力学

• 市場影響要因
• 促進要因
  • 大規模なシーケンシングプロジェクトに対する取り組みと資金の増加
  • 様々な分野でのメタゲノミクスの大きな応用
• 抑制要因
  • 新興諸国における予算の制約
  • 熟練した専門家の不足
• ビジネスチャンス
  • データ管理のためのクラウドコンピューティングの台頭
• 影響度分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 臨床試験
• 価格設定分析
• 規制の分析
• 保険償還の分析
• アンメットニーズ

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、あるいは将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 製品・サービス別

• インスツルメンツ
• 試薬・消耗品
• 分析・データ解析ソリューション
• サービス
• その他

第8章 ワークフロー別

• データ処理・解析
• サンプル調製・ライブラリー作成
• シーケンシング

第9章 技術別

• ショットガン・メタゲノムシーケンス
• 16S rRNAシーケンス
• 全ゲノムシークエンシング＆デノボアセンブリ
• メタトランススクリプトミクス

第10章 アプリケーション別

• 創薬
• 臨床診断
• 動物用医薬品
• 生態・環境分野への応用
• 産業分野への応用
• 土壌マイクロバイオーム応用
• その他

第11章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東とアフリカ

第12章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A（合併・買収）分析

第13章 企業プロファイル

• Thermo Fisher Scientific Inc.
  • 企業概要
  • 製品ポートフォリオと説明
  • 主なハイライト
  • 財務概要
• Qiagen N.V.
• BGI Group
• DNAstar, Inc.
• Eurofins Scientific
• Illumina, Inc.
• Macrogen, Inc.
• Oxford Nanopore Technologies Ltd.
• NuGEN Technologies, Inc.（A Wholly Owned Subsidiary of Tecan Trading AG）
• F. Hoffmann-La Roche Ltd.
• Perkinelmer, Inc.
• Integragen SA
• Microsynth AG
• Novogene Co., Ltd.
• Zymo Research Corporation（List Not Exhaustive）

第14章 DataM

Market Overview

Metagenomic Sequencing Market is expected to grow at a CAGR of 19.3% during the forecasting period (2022 - 2029). Metagenomics is a research field where genomic analysis of microbial DNA from environmental communities is studied. Metagenomic sequencing techniques enable scientists to analyze genes in a given sample. The method allows researchers to assess bacterial diversity and identify the presence of microbes in various environments. Steps involved in metagenomics sequencing include DNA extraction, library preparation, sequencing, assembly, annotation, and statistical analysis.

The Metagenomic Sequencing market study analysis offers an in-depth outlook on the market containing both quantitative, and qualitative data. It gives an outlook and forecast of the global market based on the Metagenomic Sequencing segmentation by product & service, workflow, and application. It also provides metagenomic sequencing market size, and growth, along with the latest trends, opportunities, and forecast till 2029 for the global metagenomic sequencing market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.

Market Dynamics

The global metagenomic sequencing market growth driven by certain factors such as advanced technological platforms and improved genomic tools, increasing initiatives and funds by government and private organizations to large scale projects of sequencing are among the key factors driving the market growth.

Advanced technological platforms and improved genomic tools, is expected to drive the global metagenomic sequencing market during the forecast period;

One of the major factors driving the growth of the metagenomic sequencing market is the continuous development of faster sequencing techniques and advancements in different methods to cope with the huge data generated, which are expanding researchers' capacity to analyze microbial communities from an unlimited variety of environments.

The growing adoption of advanced bioinformatics tools, high throughput screening (HTS) methods, recovery of novel drugs, and development of cost-effective technologies such as next-generation sequencing (NGS) are driving the market growth. The development of Next Generation DNA Sequencing (NGS) technology has driven molecular biology research, leading to several discoveries and new insights. Next-generation DNA sequencing technology goes beyond long-established DNA sequencing with its applications that reach across the principles of molecular biology.

On May 28, 2019, a precision medicine biotechnology company, Macrogen, Inc. received South Korean accreditation of Good Clinical Lab Practices from the country's Ministry of Food and Drug Safety (MFDS) and designated as a clinical trial specimen analysis institution. It would benefit Macrogen with improvised clinical diagnostic metagenomics.

Hence, increasing technological advancements regarding DNA sequencing is expected to drive market growth over the forecast period.

Increasing initiatives and funds by government and private organizations to large scale projects of sequencing

The growing awareness of genetic disorders and increasing government initiatives and funds for large-scale projects of sequencing are among the major factor driving the growth of the global metagenomic sequencing market. For instance, in 2019, QIAGEN got into a partnership with multiple organizations in the UK to support and establish its global genomics campus in Manchester (UK). The new Genomic Health Innovation Campus will aim at innovation in life sciences, translational sciences, and the molecular diagnostics field.

Also, in November 2019, The "Million Microbiome of Humans Project" (MMHP) was officially launched at the 14th International Conference on Genomics (ICG-14). Scientists from China, France, Sweden, Denmark, Latvia, and other countries will cooperate in microbial metagenomic research, aiming to sequence and analyze one million microbial samples from intestines, skin, mouth, reproductive tract, and other organs in the next 3-5 years to draw a microbiome map of the human body and build the world's largest database of the human microbiome.

Factors hampering the growth of the metagenomic sequencing market

However, the market growth is hampered by several factors such as growing concerns towards the standardization and accuracy of diagnostic testing, its requirement for parallel advancement in various isolation and identification techniques, more efficient & robust bioinformatics tools, and lack of skilled professionals.

Segmentation Analysis

The shotgun metagenomic sequencing technology segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

By technology, the metagenomic sequencing market is segmented into 16S rRNA sequencing, shotgun metagenomic sequencing, whole-genome sequencing & de-novo assembly, and metatranscriptomics. Out of all these segments, the shotgun metagenomic sequencing technology is growing at the fastest growth rate over the forecast period, due to the growing adoption of shotgun metagenomic sequencing among researchers and healthcare professionals, several advantages offered by shotgun sequencing compared with other techniques, and the increasing number of metagenomic sequencing-based research activities. Shotgun sequencing can detect low abundance members of microbial communities. Shotgun metagenome sequencing can target all genes from all organisms found in an environmental sample, in contrast to the whole sequencing and targeting all genes from only one organism.

Geographical Analysis

North America region holds the largest market share of the global Metagenomic Sequencing market

North America region is dominating the global metagenomic sequencing market accounted for the largest market share in 2019, owing to technological advancements in the next-generation sequencing procedures along with its increasing applications, favorable initiatives by government and private bodies for the development and adoption of NGS-based metagenomics technologies, the wide adoption of metagenomic diagnostics in the region, and rising awareness of metagenomics sequencing services. The market players are collaborating to introduce new procedures with innovative technology. For instance, In 2019, Illumina and Thermo Fisher Scientific (U.S.) entered into a commercial agreement for the sales of Thermo Fisher's Ion AmpliSeq technology to researchers who use Illumina's NGS platforms.

Competitive Landscape

The metagenomic sequencing market is highly competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen N.V., BGI Group, DNAstar, Inc., Eurofins Scientific, Macrogen, Inc., Oxford Nanopore Technologies Ltd., Brooks Automation, Inc. (GENEWIZ), Perkinelmer, Inc., among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the metagenomic sequencing market globally. For instance,

In 2019, Illumina acquired Pacific Biosciences, one of the leading providers of sequencing systems. This helped Illumina strengthen its sequencing product portfolio.

In 2019, Illumina acquired Edico Genome, a software provider for NGS.

In 2019, Microba had partnered with Macrogen to develop microbiome research services for international markets.

In 2019, Eurofins Scientific acquired TestAmerica, a leading environmental testing laboratory group in the US. This helped Eurofins strengthen its presence in the US market.

In November 2018, Brooks Automation, Inc. acquired the GENEWIZ group which will improve the company's global services of metagenomics sequencing.

In 2017, QIAGEN acquired Microsoft Corporation (US), management, visualization, and analysis software provider for bioinformatics, NGS, and cancer genomics.

COVID-19 Impact Analysis

The metagenomic sequencing market is positively impacted by COVID-19 as, throughout the COVID-19 pandemic, testing is a critical component of the response and rapidly increasing, which enables rapid identification and isolation of infected individuals. The Majority of this testing is PCR-based, detecting the presence of the SARS-CoV-2 virus only.

Next-generation sequencing (NGS) of the COVID-19 virus is providing powerful metagenomic data, that is combined with clinical data to search for effective treatments. Continous genomic and epigenomic analysis of SARS-CoV-2 is critical, used to determine the number of virus strains, how the virus is spread into new regions, number of introductions of the virus if there is community spread of the virus if outbreaks are linked, and how the virus is evolving.

Oxford Nanopore Technologies is doing the Metagenomic analysis of SARS-CoV-2 respiratory samples via Sequence-Independent Single Primer Amplification (SISPA) and nanopore sequencing.

Industry Analysis

The global metagenomic sequencing market provides in-depth analysis of the market based on various industry factors such as porter's five force analysis, supply chain analysis, regulatory analysis, clinical trials, pricing analysis etc, unmet needs, reimbursement analysis.

Key Companies to Watch

Illumina, Inc

Overview: Illumina, Inc. was incorporated in April 1998, and headquarter located in San Diego, California. The company develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serve the sequencing, genotyping and gene expression, and proteomics markets.

Product Portfolio: The company's product portfolio includes a wide range of highly interconnected products, including sequencing, genotyping, gene expression, and molecular diagnostic products. Illumina also offers metagenomic sequencing services, which further strengthens its market position.

Key Development: In 2019, Illumina and Lundbeck Foundation GeoGenetics Centre (Denmark) collaborated to generate one of the largest ancient genome datasets. This partnership will also help explore the relationship between the evolutionary history of select mental & neurological disorders and infectious pathogens.

The global metagenomic sequencing market report would provide an access to an approx. 40+ market data table, 45+ figures and 180 pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

• 3.1. Market Snippet by Product & Service
• 3.2. Market snippet by Technology
• 3.3. Market snippet by Workflow
• 3.4. Market Snippet by Application
• 3.5. Market Snippet by Region

4. Market Dynamics

• 4.1. Market Impacting Factors
• 4.2. Drivers
  • 4.2.1. Increasing initiatives and funding for large-scale sequencing projects
  • 4.2.2. Large applications of metagenomics in various fields
  • 4.2.3. XX
• 4.3. Restraints
  • 4.3.1. Budget constraints in developing countries
  • 4.3.2. Lack of skilled professionals
  • 4.3.3. XX
• 4.4. Opportunity
  • 4.4.1. Emerging cloud computing for data management
• 4.5. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Forces Analysis
• 5.2. Supply Chain Analysis
• 5.3. Clinical Trials
• 5.4. Pricing Analysis
• 5.5. Regulatory Analysis
• 5.6. Reimbursement Analysis
• 5.7. Unmet Needs

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product & Service

• 7.1. Introduction
• 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service Segment
• 7.3. Market Attractiveness Index, By Product & Service Segment
  • 7.3.1. Instruments*
    • 7.3.1.1. Introduction
    • 7.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3.2. Reagents & Consumables
  • 7.3.3. Analyses & Data Interpretation Solutions
  • 7.3.4. Services
  • 7.3.5. Others

8. By Workflow

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 8.1.2. Market Attractiveness Index, By Workflow Segment
• 8.2. Data Processing & Analysis *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
• 8.3. Sample Processing & Library Preparation
• 8.4. Sequencing

9. By Technology

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Segment
  • 9.1.2. Market Attractiveness Index, By Technology Segment
• 9.2. Shotgun Metagenomic Sequencing*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
• 9.3. 16S rRNA Sequencing
• 9.4. Whole Genome Sequencing & De Novo Assembly
• 9.5. Metatranscriptomics

10. By Application

• 10.1. Introduction
• 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application Segment
• 10.3. Market Attractiveness Index, By Application Segment
  • 10.3.1. Drug Discovery*
    • 10.3.1.1. Introduction
    • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 10.3.2. Clinical Diagnostics
  • 10.3.3. Veterinary Applications
  • 10.3.4. Ecological and Environmental Applications
  • 10.3.5. Industrial applications
  • 10.3.6. Soil Microbiome Applications
  • 10.3.7. Others

11. By Region

• 11.1. Introduction
• 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
• 11.3. Market Attractiveness Index, By Region
• 11.4. North America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
  • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.4.7.1. The U.S.
    • 11.4.7.2. Canada
    • 11.4.7.3. Mexico
• 11.5. Europe
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
  • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.5.7.1. Germany
    • 11.5.7.2. The U.K.
    • 11.5.7.3. France
    • 11.5.7.4. Italy
    • 11.5.7.5. Spain
    • 11.5.7.6. Rest of Europe
• 11.6. South America
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
  • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.6.7.1. Brazil
    • 11.6.7.2. Argentina
    • 11.6.7.3. Rest of South America
• 11.7. Asia Pacific
  • 11.7.1. Introduction
  • 11.7.2. Key Region-Specific Dynamics
  • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
  • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 11.7.7.1. China
    • 11.7.7.2. India
    • 11.7.7.3. Japan
    • 11.7.7.4. Australia
    • 11.7.7.5. Rest of Asia Pacific
• 11.8. The Middle East and Africa
  • 11.8.1. Introduction
  • 11.8.2. Key Region-Specific Dynamics
  • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product & Service
  • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Workflow
  • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology
  • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Thermo Fisher Scientific Inc.*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio and Description
  • 13.1.3. Key Highlights
  • 13.1.4. Financial Overview
• 13.2. Qiagen N.V.
• 13.3. BGI Group
• 13.4. DNAstar, Inc.
• 13.5. Eurofins Scientific
• 13.6. Illumina, Inc.
• 13.7. Macrogen, Inc.
• 13.8. Oxford Nanopore Technologies Ltd.
• 13.9. NuGEN Technologies, Inc. (A Wholly Owned Subsidiary of Tecan Trading AG)
• 13.10. F. Hoffmann-La Roche Ltd.
• 13.11. Perkinelmer, Inc.
• 13.12. Integragen SA
• 13.13. Microsynth AG
• 13.14. Novogene Co., Ltd.
• 13.15. Zymo Research Corporation (List Not Exhaustive)

14. DataM Intelligence

• 14.1. Appendix
• 14.2. About Us and Services
• 14.3. Contact Us